Lupin inks license and supply deal with Galenicum for Semaglutide in 23 countries

Strategic Transactions View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹2165.00

prior close

₹2168.30

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.0%-0.2% vs market

Pharmaceuticals peers, median of 156sector-1.0%-0.2% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.4

15m

+1.1

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-1.0-0.2-1.0-0.2

Next day

+0.3+0.2+0.1+0.1+0.2

-1.2-1.5+0.3-1.4+0.2

-0.3-1.0+0.7-1.7+1.4

-1.5+0.6-2.1-0.8-0.7

-2.0+0.7-2.7-1.1-0.9

-1.6-0.4-1.2-0.3-1.3

15d

+2.5+4.3-1.8+2.6-0.1

+3.8+2.6+1.2-0.2+4.0

+5.8-8.9+14.6-9.6+15.3

+6.8+3.8+3.0+2.5+4.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin's subsidiary LAHSA has signed a licensing and supply agreement with Spain-based Galenicum Health for injectable Semaglutide, a GLP-1 therapy used for Type 2 Diabetes and obesity. Galenicum will handle development, manufacturing and supply, while Lupin will manage regulatory approvals, commercialization and distribution across 23 countries including Canada, Europe, Southeast Asia and Latin America. The deal is aimed at tapping the fast-growing global GLP-1 market and expanding Lupin's diabetes and obesity portfolio beyond India.

Likely market impact

Positive for growth outlook. Opens Lupin into the booming GLP-1 weight-loss and diabetes segment across 23 countries, though financial terms were not disclosed.